Although much of the focus of therapeutic targeting of Axl in cancer is on receptor inhibitors, these studies point to the potential value of inhibiting MICAL2 or SRF/MRTF-A signaling to block the effects of elevated Axl in cancer. Here, SRF is linked to cancer.